Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Diffuse Large B-Cell Lymphoma (DLBCL): A Study of Brentuximab Vedotin Incorporated into Reduced-Dose Chemotherapy in Elderly Patients

Research Question:
What is the effect of brentuximab vedotin incorporated into dose-reduced chemotherapy for elderly patients with Diffuse Large B-Cell Lymphoma?

Basic Study Information

Purpose:
This study incorporates brentuximab vedotin into dose-reduced chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone) as initial therapy for elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). Vincristine, which is typically part of the standard chemotherapy regimen, will be omitted due to overlapping toxicities with brentuximab vedotin.

Location: University of Rochester Medical Center
Study Reference #: ULYM15105

Lead Researcher (Principal Investigator)

Lead Researcher:  Patrick Reagan

Study Contact Information

Study Coordinator: Yelena Lerman
Phone: (585) 276-8333
Email: ylerman@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search